ArticleEmerging microbes & infections2025
Rinderine suppresses African swine fever virus replication in porcine alveolar macrophages by dual targeting of membrane-associated profilin 1 and phosphatidylethanolamine.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is a highly contagious disease caused by African swine fever virus (ASFV), posing a serious threat to the global pig industry. Natural small molecules have been reported to exhibit anti-ASFV potential. This study utilized the previously established high-throughput platform for screening ASFV inhibitors to identify rinderine (RIN), a pyrrolizidine alkaloid that not only significantly inhibits ASFV replication but also maintains sustained anti-ASFV activity at 24, 48, and 72 hours postinfection. Moreover, RIN mainly suppresses the early stages of ASFV replication, particularly by inhibiting ASFV attachment to primary porcine alveolar macrophages (PAMs). Mechanistically, mass spectrometry-based cellular thermal shift assay, further experimental validation and molecular docking analysis indicate that profilin 1 (PFN1) is a key target protein mediating the inhibitory effects of RIN on ASFV attachment to PAMs. Structural prediction analysis, co-immunoprecipitation assay, and confocal microscopy demonstrate that RIN disrupts the interaction between PFN1 and actin, thereby decreasing the actin remodelling. Notably, untargeted metabolomics profiling and further experiments reveal that RIN reduces the phosphatidylethanolamine level derived from the glycerophospholipid metabolism pathway and decreases the membrane permeability of PAMs, contributing to its anti-ASFV activity. In conclusion, integrative proteomics and untargeted metabolomics analyses demonstrate that RIN exerts the antiviral effects against ASFV primarily by targeting proteins and metabolites associated with cell membrane formation and function, providing a novel insight into the prevention and control of ASF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.